Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2004

View Archived Issues

Promising atypical antipsychotic agent by Sigma-Tau

Sesame oil shows beneficial effects in hypertensive patients

Bispecific antibody targets EGFR-positive bile duct carcinoma

Promising nonpeptide galanin receptor agonist for treatment of epilepsy, depression and pain

Phytoestrogen shows vasodilating effects in vitro

MediGene acquires anticancer drugs and technology of Munich Biotech

Methanobactin: a novel peptide with antioxidant and antibiotic properties

Pfizer scientists describe new antiangiogenic agents for ocular disorders

New PI3K inhibitors and their use claimed by Pfizer

Novel PDE4 inhibitors discovered by Zambon researchers

Dual angiotensin/endothelin antagonists prepared and tested at Kyowa Hakko

Novel allosteric modulators of muscarinic receptors for psoriasis and other disorders

Vernalis presents new antibacterial agents in a recent patent

Preliminary phase II results for XMP-629

Chiron to produce pandemic-like influenza vaccines for NIAID testing

Replidyne obtains rights to faropenem daloxate

Nabi completes milestones in StaphVAX development

Chronic toxicity study completed for MDI-P

Fast track status for temsirolimus for first-line treatment of advanced RCC

Canadian approval for Tiazac XC

Priority review for new 500-mg formulation of Invirase

Paradigm Genetics changes name to Icoria

Antegren submitted for approval in Canada

Genzyme makes important progress during second quarter

Endo highlights recent developments

Nippon Shinyaku presents novel potent non-prostanoid prostacyclin agonist

Novel non-competitive AMPA antagonist shows potent neuroprotective activity in vivo

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026